Seaport Therapeutics and Hemab filed S-1 registration statements with the SEC within hours of each other, joining a narrow queue of sub-$500M market cap biotechs attempting public listings before the summer lull. Seaport, a neuroscience platform spun out of Karuna Therapeutics assets, is targeting $75M to $100M in gross proceeds. Hemab, a rare bleeding disorder specialist with a Phase III hemophilia A asset, filed for a similar range. Both companies are working with syndicates anchored by mid-tier banks—Seaport with Jefferies and Leerink, Hemab with Cowen and SVB Securities.

The filings arrive as Kailera Therapeutics priced its own IPO at $16 per share, raising $101M and trading flat in its debut session. Kailera's performance—neither a pop nor a crater—suggests institutional allocators are willing to underwrite clinical-stage stories again, but only at disciplined entry points. Seaport's lead program, SPN-830, is a TAAR1 agonist in Phase II for major depressive disorder, a crowded indication with half a dozen competitors. Hemab's palovarotene targets heterotopic ossification in hemophilia A patients, a narrow label with $200M peak sales estimates from sell-side models. Neither company has disclosed existing institutional ownership beyond founding venture syndicates.

This matters because the biotech IPO window has been functionally closed since mid-2022, with only nine venture-backed biotech IPOs pricing in 2023 and six in the first half of 2024, down from 79 in 2021. Family offices and crossover funds that bought into late-stage private rounds at $400M to $600M pre-money valuations are now staring at extension rounds or down-round public listings. Seaport and Hemab are testing whether the market will absorb $75M to $100M offerings for single-asset platforms with 18 to 24 months of cash runway post-IPO. If both price, it signals that the venture-to-public bridge is reopening for companies willing to accept $300M to $400M post-money valuations, roughly half the 2021 benchmarks. If either pulls its filing, the window likely stays shut until after the Fed's September meeting.

Operators should watch three things: whether Seaport and Hemab price within 45 days, whether their opening-day trading shows institutional accumulation or retail churn, and whether a third or fourth filing follows in the next 30 days. A cluster of three or more IPOs in a six-week span historically marks a durable reopening. Allocators need to track whether crossover funds that sat out the past 18 months are participating in these syndicates or staying on the sidelines. The tell will be in the amended S-1 filings, typically published 10 to 14 days before pricing, which list cornerstone investors.

Kailera's $16 price and flat debut suggest the market is willing to clear, but not reward. That is enough for biotechs sitting on 12 months of cash to roll the dice.